

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

**Draft Minutes**  
**Electronic Meeting of the Toxicology Subcommittee**  
**of the Scientific Advisory Committee**  
**October 11, 2023 @ 9 a.m.**  
**Department of Forensic Science**

**Subcommittee Members Present**

Randall E. Beaty  
Marc A. LeBeau, Ph.D., *Chair*  
Richard P. Meyers

**Staff Members Present**

David A. Barron, Ph.D., Deputy Director  
Mason Byrd, Chief Deputy Director  
Deea Chakraborty, Legal Assistant  
Sabrina Cillessen, Physical Evidence Program Manager  
James W. Hutchings, Ph.D., Toxicology Program Manager  
Linda C. Jackson, Director  
Amy C. Jenkins, Department Counsel  
Melissa Lloyd, Forensic Scientist Group Supervisor  
Alka B. Lohmann, Director of Technical Services  
Jessica B. Norton, Legal Assistant  
Elise Stroble, Grants and Administration Program Manager  
Jayne Thatcher, Toxicology Section Supervisor  
Rebecca Wagner, Ph.D., Research Section Supervisor

**Call to Order by Subcommittee Chair**

Dr. LeBeau called the meeting of the Toxicology Subcommittee (“Subcommittee”) to order at 9:02 a.m.

**Adoption of Agenda**

Dr. LeBeau advised that the first order of business was the adoption of the draft agenda for the meeting and noted that the agenda was previously shared with the Subcommittee members. Mr. Meyers made a motion to adopt the agenda, which was seconded and passed by unanimous vote of the Subcommittee.

**Adoption of Draft Minutes from the April 20, 2022 Subcommittee Meeting**

Dr. LeBeau noted that the draft minutes from the April 20, 2022 meeting of the Subcommittee were previously shared and asked if there were any proposed changes. Being none, Mr. Beaty made a motion that the minutes be approved, which was seconded and adopted by unanimous vote.

**Discussion of Validation Summaries and Plans**

In advance of the meeting, the members of the Subcommittee were provided copies of validation plans and summaries for the following methods:

- Validation Plan - Addition of Xylazine and Dexmedetomidine to the Opioid, Cocaine, Benzoyllecgonine and Cocaethylene Quantitation and Confirmation by LCMSMS Method

- 47 • Validation Plan - Addition of Xylazine to the Acid/Base/Neutral Drug Screen and  
48 Quantitation by GC and GC-MS using the Liquid-Liquid Extraction Option  
49 • Validation Plan - Phencyclidine (PCP), Ketamine, and Dextromethorphan (Dxm)  
50 Quantitation and Confirmation by Solid Phase Extraction Using LCMSMS  
51 • Validation Summary - Cannabinoids Quantitation and Confirmation by Supported Liquid  
52 Extraction Using LCMSMS  
53 • Validation Summary - Qualitative Screening and Confirmation of Xylazine by the Acid,  
54 Base, and Neutral Drugs Screen  
55

56 Dr. Wagner provided an overview of each of the validation plans and summaries. The  
57 Subcommittee members asked questions, which were answered by Dr. Wagner and Dr. Hutchings.  
58 Some recommendations for consideration were made for the validation summary on a method to  
59 screen and confirm Xylazine.  
60

61 After the discussion period, Mr. Beaty made a motion to close the review of the five validation  
62 plans and summaries, which was seconded and passed by unanimous vote of the Subcommittee.  
63

#### 64 **Public Comment**

65 No member of the public was present to provide comment.  
66

#### 67 **Adjournment**

68 Dr. LeBeau asked for a motion to adjourn the meeting. Mr. Meyers made a motion to adjourn the  
69 meeting, which was seconded and passed by unanimous vote of the Subcommittee. The meeting  
70 adjourned at 9:34 a.m.